Recent Updates
Recently added Catalysts

BGE-102

Phase 2

Obesity and Cardiovascular Risk | Small molecule | Metabolic |BioAge Labs, Inc.|Last Updated: Jun 18, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment160
FDA Designations
No designations recorded
Clinical trial landscape

BGE-102 · 1 trial · 1 indication

Phase 2 1
NCT07656727A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsObesity and Cardiovascular Risk
RECRUITING160 Analytics
PHASE2RECRUITING
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Obesity and Cardiovascular Risk
NCT07656727160
Unlock trial analytics
Study Endpoints
Primary Endpoints
Percent change in hsCRP (Dose A)
Week 12

Percent change in hsCRP of the BGE-102 Dose A daily compared to Placebo

Percent change in hsCRP (Dose B)
Week 12

Percent change in hsCRP of the BGE-102 Dose B daily compared to Placebo

Percent change in hsCRP (Dose C)
Week 12

Percent change in hsCRP of the BGE-102 Dose C daily compared to Placebo

Secondary Endpoints
Incidence of serious adverse events (SAEs)
Up to Week 16
Incidence of treatment-emergent adverse events (TEAEs)
Up to Week 16
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm A: BGE-102 Dose AEXPERIMENTALcapsules dosed once daily in the morning
Arm B: BGE-102 Dose BEXPERIMENTALcapsules dosed once daily in the morning
Arm C: BGE-102 Dose CEXPERIMENTALcapsules dosed once daily in the morning
Arm D: Dose DPLACEBO_COMPARATORcapsules dosed once daily in the morning
Interventions
NameTypeDescription
Oral BGE-102DRUGCapsules
Oral Placebo Matching BGE-102DRUGCapsules
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites13

Key Inclusion Criteria: * Obese Male and Female adults with BMI 32-42 kg/m² * Elevated blood test for hsCRP consistent with chronic systemic inflammation * At least one cardiovascular risk factor or metabolic syndrome feature * Stable background therapies and willing to maintain stable diet/exercis...

Countries:United StatesPuerto Rico
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 18, 2026NCT07656727NEW_TRIAL: changed
LOWJun 18, 2026NCT07656727NEW_TRIAL: changed
LOWJun 18, 2026NCT07656727NEW_TRIAL: changed